Silence Therapeutics (SLN) Operating Margin (2024 - 2026)

Silence Therapeutics has disclosed Operating Margin across 3 years of filings, most recently posting 3729.15% for Q1 2026.

• Operating Margin for Q1 2026 came in at 3729.15%, up 1627719.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 1162.94% (down 85196.0% YoY), and the FY2025 annual result was 3962.43%, down 381606.0% from the prior year.
• Operating Margin came in at 3729.15% for Q1 2026 at Silence Therapeutics, down from 166076.47% in the prior quarter.
• In the past five years, Operating Margin ranged from a high of 166076.47% in Q4 2025 to a low of 20006.34% in Q1 2025.
• The 3-year median for Operating Margin is 3093.65% (2024), against an average of 12078.33%.
• Peak annual rise in Operating Margin reached 16609367 bps in 2025, while the deepest fall reached 1997079 bps in 2025.
• Silence Therapeutics' Operating Margin stood at 17.2% in 2024, then surged by 965763 bps to 166076.47% in 2025, then sank by 102 bps to 3729.15% in 2026.
• The last three Operating Margin figures came in at 3729.15% (Q1 2026), 166076.47% (Q4 2025), and 16505.66% (Q3 2025), per Business Quant data.